<DOC>
	<DOC>NCT01316861</DOC>
	<brief_summary>The Purpose of This Study is to Evaluate the Efficacy and Safety of Acarbose in Type 2 Diabetic Patients Using Two Different Formulations of Acarbose 50mg.</brief_summary>
	<brief_title>Efficacy and Safety of Oral Acarbose Treatment in Patients With Type 2 Diabetes Mellitus</brief_title>
	<detailed_description>Study Design: - Multicenter - Phase III - Randomized - Double Blind - Prospective and Comparative - Experiment duration: 105 days - 5 visits - Efficacy - Adverse event</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Acarbose</mesh_term>
	<criteria>Patients must be able to understand the study procedures agree to participate and give written consent. Diagnosed with type 2 diabetes mellitus (t2dm)b Female patients of childbearing potential (i.e., ovulating, premenopausal, not surgically sterile) which agree to use a medically accepted contraceptive regimen for the duration of the study. Pregnancy or risk of pregnancy. Lactation Any pathology or past medical condition that can interfere with this protocol Other conditions deemed reasonable by the medical investigator as to the disqualification of the individual from study participation. Known hypersensitivity / intolerance to acarbose or any of its excipients</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2013</verification_date>
</DOC>